Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data YD Bio Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2025
FY2025
Revenue
0.35
0.51
0.6
Cost of revenue
0.2
0.36
0.43
Gross profit
0.15
0.16
0.17
Research and development
0.49
1.6
Selling and marketing
0.01
0
0.17
General and administrative
0.15
1.12
3.66
Operating expenses
0.16
1.62
5.44
Operating income
-0.01
-1.46
-5.27
Interest expense
0
0
Interest income
0
0.01
0.08
Other non-operating income
0.03
0.08
-3.04
Pre-tax income
0.02
-1.39
-8.31
Income tax
0
0.03
-0
Net income
0.01
-1.41
-8.31
EBITDA
-0.01
-1.45
-5.26
EPS, basic
0.00
-0.02
-0.12
EPS, diluted
0.00
-0.02
-0.12
Shares, basic (weighted)
64.7
64.7
66.7
Shares, diluted (weighted)
64.7
64.7
66.7
Balance sheet
FY2023
FY2025
FY2025
Cash and equivalents
0.09
3.13
6.01
Receivables
0.09
0.17
Inventory
0.04
1.88
Other current assets
0.19
1.32
Total current assets
3.47
9.67
Property, plant and equipment
0.06
0.06
Lease right-of-use assets
0.02
0.01
Intangible assets
2.68
2.61
Total assets
6.86
13.8
Accounts payable
0.03
0.41
Accrued liabilities
0.15
0.4
Deferred revenue
0.03
0.03
Total current liabilities
0.26
1.64
Long-term debt
0.01
Lease liabilities
0.01
Total liabilities
0.27
16.6
Total debt
0.01
Paid-in capital
8.47
7.16
Retained earnings
-1.93
-10.2
Other comprehensive income
0.05
0.21
Shareholders' equity
0.02
6.59
-2.86
Total equity
0.02
6.59
-2.86
Total liabilities and equity
6.86
13.8
Shares outstanding
64.7
70.8
Cash flow statement
FY2023
FY2025
FY2025
Net income
0.01
-1.41
-8.31
Depreciation and amortization
0
0.01
0.02
Deferred income tax
0
0.03
-0
Change in receivables
-0.06
0.01
-0.08
Change in inventory
-0.03
0.03
-1.84
Change in payables
0.01
0.01
0.39
Cash from operations
-0.06
-1.22
-6.6
Capital expenditures
-0
-0.07
-1.44
Cash from investing
-0
-2.9
-1.44
Debt repaid
-0.03
-0.03
Stock issued
7.55
13.2
Cash from financing
0.11
7.11
10.9
Net change in cash
0.06
3.05
2.88
Free cash flow
-0.06
-1.3
-8.04
Interest paid
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $5.73 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
28.1%
Gross profit / revenue.
Operating margin
-883.3%
Operating income / revenue.
EBITDA margin
-880.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-1,393.0%
Pre-tax income / revenue.
Net margin
-1,393.0%
Net income / revenue.
FCF margin
-1,347.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-1,105.0%
Cash from operations / revenue.
Return on assets (ROA)
-80.5%
Net income / average total assets.
R&D / revenue
268.4%
Research and development expense / revenue.
Capex / revenue
241.3%
Capital expenditures / revenue.
D&A / revenue
2.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
16.9%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
7.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-143.3%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
100.7%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
3.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.88x
Current assets / current liabilities.
Quick ratio
3.76x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.66x
(Cash + short-term investments) / current liabilities.
Debt / assets
0.0%
Total debt / total assets.
Liabilities / assets
120.7%
Total liabilities / total assets.
Net debt
-$6.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.12
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.12
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.01
Revenue / diluted weighted shares.
FCF per share
-$0.12
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.10
Cash from operations / diluted weighted shares.
Book value per share
-$0.04
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
680x
Market cap / revenue.
EV/Sales
670x
Enterprise value / revenue.
FCF yield
-2.0%
Free cash flow / market cap.
Earnings yield
-2.0%
Net income / market cap (the inverse of P/E).
What was YD Bio Ltd's revenue in fiscal 2025?
YD Bio Ltd reported revenue of $596.8K for fiscal 2025, 16.9% higher than the year before.
Was YD Bio Ltd profitable in fiscal 2025?
No. It reported a net loss of $8.3M.
How much free cash flow did YD Bio Ltd generate in fiscal 2025?
Cash from operations of $6.6M minus capital expenditures of $1.4M left free cash flow of -$8.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.